Extremely Informative Stock: {DexCom, Inc. (NASDAQ: DXCM)
DexCom, Inc. (NASDAQ: DXCM) changed 0.00% to recent value of $216.4. The stock transacted 215257 shares during most recent day however it has an average volume of 977.56K shares. It spotted trading -6.72% off 52-week high price. On the other end, the stock has been noted 104.71% away from the low price over the last 52-weeks.
DexCom, Inc. (DXCM) recently stated its financial results as of and for the quarter ended September 30, 2019.
Third Quarter 2019 Highlights:
Revenue grew 49% versus the same quarter of the previous year to $396.3M
U.S. revenue growth of 53% and international revenue growth of 36%
GAAP operating income of $56.0M or 14% of revenue, a raise of 890 basis points contrasts to the third quarter of 2018. Non-GAAP operating income* of $59.1M or 15% of revenue, a raise of 940 basis points over the third quarter of 2018.
3-Year COMISAIR1 study results continued to demonstrate the value proposition of Dexcom’s real-time CGM:
Important improvements to A1C and time in range for Dexcom CGM subgroups regardless of one’s method of insulin delivery
Time in range increased by over 20% for CGM use in conjunction with both MDI and pump cohorts, nearly 5 hours per day of additional glycemic control
Third Quarter 2019 Financial Results
Revenue: In the third quarter of 2019, worldwide revenue grew 49% to $396.3M, up from $266.7M in the third quarter of 2018. Volume growth in conjunction with strong new patient additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases.
Gross Profit: Gross profit totaled $246.9M or 62.3% of sales for the third quarter of 2019, contrast to $168.6M or 63.2% of sales in the third quarter of 2018.
Operating Income: GAAP operating income for the third quarter of 2019 was $56.0M, contrast to a GAAP operating income of $13.9M for the third quarter of 2018.
Non-GAAP operating income* for the third quarter of 2019 was $59.1M, contrast to a non-GAAP operating income of $14.7M for the third quarter of 2018. The third quarter 2019 non-GAAP amount excludes $2.8M of business transition and related costs and the third quarter 2018 non-GAAP amount excludes $0.8M of such costs.
Net Income and Net Income per Share: GAAP net income was $45.8M, or $0.50 per diluted share, for the third quarter of 2019, contrast to GAAP net income of $46.6M, or $0.52 per diluted share, for the same quarter of 2018. GAAP net income for the third quarter of 2018 included $34.9M of income from equity investments.
Non-GAAP net income* was $60.4M, or $0.65 per diluted share, for the third quarter of 2019, contrast to a non-GAAP net income of $15.9M, or $0.18 per share, for the same quarter of 2018. The third quarter 2019 non-GAAP amount excludes $2.8M of business transition and related costs and $11.5M of non-cash interest expense related to Dexcom’s senior convertible notes. The third quarter 2018 non-GAAP amount excludes $0.8M of business transition and related costs, $3.4M of non-cash interest expense related to DexCom’s senior convertible notes, and $34.9M of income from equity investments.
Cash and Liquidity: As of September 30, 2019, Dexcom held $1.430B in cash and marketable securities and our revolving credit facility remains undrawn. The cash balance includes the net proceeds from Dexcom’s fourth quarter 2018 convertible notes offering and represents important financial and planned flexibility as Dexcom continues to expand production capacity and explore new market opportunities.
DXCM has a gross margin of 63.30% and an operating margin of -9.20% while its profit margin remained -12.70% for the last 12 months. Its earnings per share (EPS) expected to touch remained -324.80% for this year while earning per share for the next 5-years is expected to reach at 78.00%. The company has 92.78M of outstanding shares and 91.12M shares were floated in the market. According to the most recent quarter its current ratio was 5.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of -1.37% from the mean of 20 days, 11.91% from mean of 50 days SMA and performed 40.42% from mean of 200 days price. Company’s performance for the week was -0.43%, -2.46% for month and YTD performance remained 80.63%.
